Imatinib compared with second‐generation tyrosine kinase‐inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase
American Journal of Hematology · 2023
DOI: 10.1002/ajh.26943 ↗Kurz gefasst
Leserbrief in der Zeitschrift American Journal of Hematology, 2023. Verfasst von Sen Yang und 49 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Haematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University Peop…. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase. Die Arbeit nennt 5 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Nowadays, imatinib and second generation tyrosine kinase inhibitors
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Clinical Research Center for Haematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Peking University Institute of Haematology, Beijing, Ch…
- Centre for Haematology, Department of Immunology and Inflammation, Imperial College of Science, Technology and Medicine, London, UK.
- Department of Hematology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China.
- Department of Haematology, Qilu Hospital, Shandong University, Jinan, China.
- Department of Haematology, Guangdong Provincial People's Hospital, Guangzhou, China.
- Department of Haematology, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu, China.
ORCID-Profile: Sen Yang, Robert Peter Gale, Jian-da Hu, Huan-Ling Zhu, Su-Ning Chen, Wei-Ming Li, Qian Jiang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yang, S., Zhang, X., Gale, R. P., Du, X., Chen, C. Y., Weng, J. Y., Huang, J., Li, F., Zeng, Y., Xiao, Z., Hu, J. D., Yang, L. J., Liu, Z. G., Li, G. H., Sun, X. L., Yang, W., Feng, R., Han, Y. Q., Jing, Y., …, & Jiang, Q. (2023). Imatinib compared with second‐generation tyrosine kinase‐inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase. American Journal of Hematology. https://doi.org/10.1002/ajh.26943
Vancouver
Yang S, Zhang X, Gale RP, Du X, Chen CY, Weng JY, et al. Imatinib compared with second‐generation tyrosine kinase‐inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase. American Journal of Hematology. 2023. doi:10.1002/ajh.26943
BibTeX
@article{Yang2023,
author = {Yang, Sen and Zhang, Xiaoshuai and Gale, Robert Peter and Du, Xin and Chen, Chun-Yan and Weng, Jian-Yu and Huang, Jian and Li, Fei and Zeng, Yun and Xiao, Zhen and Hu, Jian-da and Yang, Li-Jie and Liu, Zhuo-Gang and Li, Guo-Hui and Sun, Xiu-Li and Yang, Wei and Feng, Ru and Han, Yan-Qiu and Jing, Yu and Xu, Na and Liu, Xiao-Li and Liu, Zhen-Fang and Wang, Xiao-Dong and Wu, Shi-Xin and Liang, Rong and Zhang, Yan-Li and Yang, Yun-Fan and Zhu, Huan-Ling and Pan, Ling and Meng, Li and Zhao, Yan-Hong and Yi, Hai and Liu, Yi-Lan and Zhang, Wei-Hua and Zheng, Yuan-Jun and Zhou, Ze-Ping and Chen, Su-Ning and Qiu, Hui-Ying and Li, Wei-Ming and Jia, Zhi-Lin and Bai, Yan-Liang and Lin, Li-E and Liu, Bing-Cheng and Liu, Chun-Shui and Luo, Jian-Min and Meng, Jun-Xia and Sun, Zhi-Qiang and Zhang, Yan-Qing and Huang, Xiao-Jun and Jiang, Qian},
title = {Imatinib compared with second‐generation tyrosine kinase‐inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase},
journal = {American Journal of Hematology},
year = {2023},
doi = {10.1002/ajh.26943}
}
EUVIMED